Hakon Leffler
11 – 20 of 166
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor : a single- and multiple-dose first-in-human study in healthy participants
(
- Contribution to journal › Article
-
Mark
Discovery of Selective and Orally Available Galectin-1 Inhibitors
(
- Contribution to journal › Article
-
Mark
Increased Galectin-9 Levels Correlate with Disease Activity in Patients with DMARD-Naïve Rheumatoid Arthritis and Modulate the Secretion of MCP-1 and IL-6 from Synovial Fibroblasts
(
- Contribution to journal › Article
- 2022
-
Mark
Engineering the Ligand Specificity of the Human Galectin-1 by Incorporation of Tryptophan Analogues
(
- Contribution to journal › Article
-
Mark
Selective Monovalent Galectin-8 Ligands Based on 3-Lactoylgalactoside
(
- Contribution to journal › Article
-
Mark
Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation
(
- Contribution to journal › Article
-
Mark
Site-specific N-glycan profiles of α5β1 integrin from rat liver
(
- Contribution to journal › Article
-
Mark
Galectin-3 Decreases 4-1BBL Bioactivity by Crosslinking Soluble and Membrane Expressed 4-1BB
(
- Contribution to journal › Article
-
Mark
Novel Selective Galectin-3 Antagonists Are Cytotoxic to Acute Lymphoblastic Leukemia
(
- Contribution to journal › Article
-
Mark
Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease
(
- Contribution to journal › Article